EdwardC.HsiaoMD
Endocrinology • San Francisco, CADiabetes, Lipid Metabolism, Osteoporosis & Bone Metabolism Medicine
Assistant Professor in Residence, Internal Medicine, UCSF School of Medicine
Dr. Hsiao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4150 Clement St
# 111N
San Francisco, CA 94121Phone+1 415-750-2089
Education & Training
University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2009
Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004- Johns Hopkins University School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2003 - 2025- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects Start of enrollment: 2014 Jul 14
Publications & Presentations
PubMed
- Personalized Approaches to Spine Surgery.Arati Patel, Abraham Dada, Satvir Saggi, Hunter Yamada, Vardhaan S Ambati
International Journal of Spine Surgery. 2024-11-15 - 1 citationsAdipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system.Lin Qi, Marko Groeger, Aditi Sharma, Ishan Goswami, Erzhen Chen
Nature Communications. 2024-09-12 - 2 citationsLong-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva.Ruby Haviv, Leonid Zeitlin, Veronica Moshe, Amit Ziv, Noa Rabinowicz
Rheumatology. 2024-09-01
Press Mentions
Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaDecember 12th, 2017
Organovo and UCSF Partner to Create 3D Bioprinted Tissues for Skeletal Disease ResearchJune 14th, 2016
FDA Approves Palovarotene for Treatment of Rare Bone DisorderAugust 18th, 2023- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
